Matrixx Banks On Oral Cold Remedies And A Severe Flu Season
This article was originally published in The Tan Sheet
Executive Summary
Migrating customers to oral forms of its Zicam cold remedies is more critical for Matrixx Initiatives now that FDA refused to reverse its order to pull from the market the intranasal version of the zinc-containing cold products
You may also be interested in...
To Rebuild Zicam, Matrixx Can Tap Into Brand's History, Pharmacists' Regard
Matrixx Initiatives' best chances for rebuilding the Zicam brand appear to be reminding consumers why they initially chose the firm's products and tapping pharmacists' insight on the efficacy of zinc-containing cold remedies
To Rebuild Zicam, Matrixx Can Tap Into Brand's History, Pharmacists' Regard
Matrixx Initiatives' best chances for rebuilding the Zicam brand appear to be reminding consumers why they initially chose the firm's products and tapping pharmacists' insight on the efficacy of zinc-containing cold remedies
To Rebuild Zicam, Matrixx Can Tap Into Brand's History, Pharmacists' Regard
Matrixx Initiatives' best chances for rebuilding the Zicam brand appear to be reminding consumers why they initially chose the firm's products and tapping pharmacists' insight on the efficacy of zinc-containing cold remedies